SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin slips on receiving warning letter from USFDA for Goa and Indore sites

07 Nov 2017 Evaluate

Lupin is currently trading at Rs. 851.00, down by 183.70 points or 17.75% from its previous closing of Rs. 1034.70 on the BSE.

The scrip opened at Rs. 1041.10 and has touched a high and low of Rs. 1044.00 and Rs. 846.20 respectively. So far 2285514 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1572.25 on 06-Feb-2017 and a 52 week low of Rs. 846.20 on 07-Nov-2017.

Last one week high and low of the scrip stood at Rs. 1070.35 and Rs. 846.20 respectively. The current market cap of the company is Rs. 38832.75 crore.

The promoters holding in the company stood at 46.80%, while Institutions and Non-Institutions held 40.05% and 13.14% respectively.

Lupin has received a warning letter issued by the United States Food and Drug Administration (USFDA) on November 6, 2017, for its formulation manufacturing facilities at Goa and Indore (Pithampur Unit II). While there will be no disruption of existing product supplies from either of these locations, there will likely be a delay of new product approvals from these two facilities.

Earlier, the company had received three Form 483 observations in Goa on April 7, 2017 and six Form 483 observations in Pithampur (Unit II) on May 19, 2017.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2303.70 -7.20 (-0.31%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×